Abraham Ceesay, Chief Executive Officer at Rapport Therapeutics, Inc. (RAPP), sold 51,499 shares at $45.97 ($2.4M) on 2026-08-10, disclosed to the SEC on 2026-08-12.
Scheduled sale ($2.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.97 | 14,171 | $651K | 26.8% |
| 2 | $46.75 | 8,370 | $391K | 16.1% |
| 3 | $46.90 | 3,664 | $172K | 7.1% |
| 4 | $48.04 | 19,500 | $937K | 38.5% |
| 5 | $48.62 | 5,794 | $282K | 11.6% |
| Total | $47.25 avg | 51,499 |
| $2.4M |
| 100% |
| Filing → |
| RAPP | SELL | 2026-08-26 | $938K | — | Filing → |
| RAPP | SELL | 2026-07-29 | $93K | — | Filing → |
| RAPP | SELL | 2026-07-15 | $328K | — | Filing → |